As of 2025-06-30, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is (19.60) USD. This relative valuation is based on P/E multiples. With the latest stock price at 326.09 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -106.0%.
The range of the Relative Valuation is (21.26) - (20.11) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 6.8x - 9.7x | 8.2x |
| Forward P/E multiples | 10.3x - 11.1x | 10.7x |
| Fair Price | (21.26) - (20.11) | (19.60) |
| Upside | -106.5% - -106.2% | -106.0% |
| Date | P/E |
| 2025-06-27 | -156.08 |
| 2025-06-26 | -153.86 |
| 2025-06-25 | -155.65 |
| 2025-06-24 | -157.12 |
| 2025-06-23 | -151.39 |
| 2025-06-20 | -149.73 |
| 2025-06-18 | -150.99 |
| 2025-06-17 | -149.25 |
| 2025-06-16 | -149.28 |
| 2025-06-13 | -148.90 |
| 2025-06-12 | -147.30 |
| 2025-06-11 | -144.35 |
| 2025-06-10 | -146.23 |
| 2025-06-09 | -146.97 |
| 2025-06-06 | -145.44 |
| 2025-06-05 | -148.91 |
| 2025-06-04 | -147.61 |
| 2025-06-03 | -146.86 |
| 2025-06-02 | -147.98 |
| 2025-05-30 | -147.24 |
| 2025-05-29 | -141.61 |
| 2025-05-28 | -138.06 |
| 2025-05-27 | -140.25 |
| 2025-05-23 | -140.18 |
| 2025-05-22 | -139.72 |
| 2025-05-21 | -141.45 |
| 2025-05-20 | -141.02 |
| 2025-05-19 | -141.10 |
| 2025-05-16 | -137.94 |
| 2025-05-15 | -137.01 |
| 2025-05-14 | -129.35 |
| 2025-05-13 | -129.02 |
| 2025-05-12 | -130.63 |
| 2025-05-09 | -121.42 |
| 2025-05-08 | -124.90 |
| 2025-05-07 | -133.70 |
| 2025-05-06 | -130.44 |
| 2025-05-05 | -132.25 |
| 2025-05-02 | -125.41 |
| 2025-05-01 | -123.35 |
| 2025-04-30 | -127.27 |
| 2025-04-29 | -124.34 |
| 2025-04-28 | -123.21 |
| 2025-04-25 | -121.62 |
| 2025-04-24 | -117.29 |
| 2025-04-23 | -116.98 |
| 2025-04-22 | -114.46 |
| 2025-04-21 | -112.53 |
| 2025-04-17 | -113.40 |
| 2025-04-16 | -111.44 |